TickerFacts.

Compare

Protalix BioTherapeutics, Inc. vs Champions Oncology, Inc. vs Kymera Therapeutics, Inc. vs Compugen Ltd

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearProtalix BioTherapeutics, Inc.
PLX		Champions Oncology, Inc.
CSBR		Kymera Therapeutics, Inc.
KYMR		Compugen Ltd
CGEN
Year ended2025-12-312026-04-302025-12-312025-12-31
Revenue$52.74M$59.42M$39.21M$72.76M
Revenue growth (YoY)-1.2%+4.4%-16.7%+161.1%
Gross margin48.8% (computed)48.0% (computed)0.0% (computed)87.3%
Operating margin-10.4%-1.9%-891.1%43.1%
Net margin-12.5%-2.0%-794.0%48.6%
Net income-$6.60M-$1.18M-$311.35M$35.34M
EPS (Diluted)-$0.08-$0.08-$3.69$0.38
Operating cash flow-$11.99M-$4.47M-$232.89M$31.63M
Free cash flow-$13.63M-$5.04M-$234.34M$31.33M
Cash & equivalents$14.68Mn/a$357.01M$90.60M
Total assets$82.35M$26.99M$1.74B$156.57M
Total liabilities$34.12M$22.92M$163.15Mn/a
Shareholders' equity$48.23M$3.94M$1.58B$102.73M
Return on year-end equity-13.7%-29.8%-19.7%34.4%
Shares outstanding80.43M13.89M81.32M94.55M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearProtalix BioTherapeutics, Inc.Champions Oncology, Inc.Kymera Therapeutics, Inc.Compugen Ltd
Latest$52.74M
Ended 2025-12-31		$59.42M
Ended 2026-04-30		$39.21M
Ended 2025-12-31		$72.76M
Ended 2025-12-31
1 year earlier$53.40M
Ended 2024-12-31		$56.94M
Ended 2025-04-30		$47.07M
Ended 2024-12-31		$27.86M
Ended 2024-12-31
2 years earlier$65.49M
Ended 2023-12-31		$50.16M
Ended 2024-04-30		$78.59M
Ended 2023-12-31		$33.46M
Ended 2023-12-31
3 years earlier$47.64M
Ended 2022-12-31		$53.87M
Ended 2023-04-30		$46.83M
Ended 2022-12-31		$7.50M
Ended 2022-12-31
4 years earlier$38.35M
Ended 2021-12-31		$49.11M
Ended 2022-04-30		$72.83M
Ended 2021-12-31		$6.00M
Ended 2021-12-31